|
1
|
Khan SA, Thomas HC, Davidson BR and
Taylor-Robinson SD: Cholangiocarcinoma. Lancet. 366:1303–1314.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Shaib Y and El-Serag HB: The epidemiology
of cholangiocarcinoma. Semin Liver Dis. 24:115–125. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Cardinale V, Semeraro R, Torrice A, et al:
Intra-hepatic and extra-hepatic cholangiocarcinoma: new insight
into epidemiology and risk factors. World J Gastrointest Oncol.
2:407–416. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Valle J, Wasan H, Palmer DH, et al:
Cisplatin plus gemcitabine versus gemcitabine for biliary tract
cancer. N Engl J Med. 362:1273–1281. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hezel AF, Deshpande V and Zhu AX: Genetics
of biliary tract cancers and emerging targeted therapies. J Clin
Oncol. 28:3531–3540. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ortner MA: Photodynamic therapy for
cholangiocarcinoma: overview and new developments. Curr Opin
Gastroenterol. 25:472–476. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gatto M, Bragazzi MC, Semeraro R, et al:
Cholangiocarcinoma: update and future perspectives. Dig Liver Dis.
42:253–260. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Blechacz BR and Gores GJ:
Cholangiocarcinoma. Clin Liver Dis. 12:131–150. 2008. View Article : Google Scholar
|
|
9
|
Mihalache F, Hoblinger A, Grunhage F, et
al: Heterozygosity for the alpha1-antitrypsin Z allele may confer
genetic risk of cholangiocarcinoma. Aliment Pharmacol Ther.
33:389–394. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhou H, Ortiz-Pallardo ME, Ko Y and
Fischer HP: Is heterozygous alpha-1-antitrypsin deficiency type PIZ
a risk factor for primary liver carcinoma? Cancer. 88:2668–2676.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hoblinger A and Lammert F: Genetics of
biliary tract diseases: new insights into gallstone disease and
biliary tract cancers. Curr Opin Gastroenterol. 24:363–371. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Blechacz B and Gores GJ:
Cholangiocarcinoma: advances in pathogenesis, diagnosis, and
treatment. Hepatology. 48:308–321. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Grivennikov SI, Greten FR and Karin M:
Immunity, inflammation, and cancer. Cell. 140:883–899. 2010.
View Article : Google Scholar
|
|
14
|
Vogelstein B, Lane D and Levine AJ:
Surfing the p53 network. Nature. 408:307–310. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Komarova EA, Krivokrysenko V, Wang K, et
al: p53 is a suppressor of inflammatory response in mice. FASEB J.
19:1030–1032. 2005.PubMed/NCBI
|
|
16
|
Gudkov AV and Komarova EA: Dangerous
habits of a security guard: the two faces of p53 as a drug target.
Hum Mol Genet. 16(Spec No 1): R67–R72. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Khan SA, Taylor-Robinson SD, Carmichael
PL, Habib N, Lemoine NR and Thomas HC: Analysis of p53 mutations
for a mutational signature in human intrahepatic
cholangiocarcinoma. Int J Oncol. 28:1269–1277. 2006.PubMed/NCBI
|
|
18
|
Khan SA, Thomas HC, Toledano MB, Cox IJ
and Taylor-Robinson SD: p53 Mutations in human cholangiocarcinoma:
a review. Liver Int. 25:704–716. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tannapfel A, Weinans L, Geissler F, et al:
Mutations of p53 tumor suppressor gene, apoptosis, and
proliferation in intrahepatic cholangiocellular carcinoma of the
liver. Dig Dis Sci. 45:317–324. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Farazi PA, Zeisberg M, Glickman J, Zhang
Y, Kalluri R and DePinho RA: Chronic bile duct injury associated
with fibrotic matrix microenvironment provokes cholangiocarcinoma
in p53-deficient mice. Cancer Res. 66:6622–6627. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Whibley C, Pharoah PD and Hollstein M: p53
polymorphisms: cancer implications. Nat Rev Cancer. 9:95–107. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bond GL, Hu W, Bond EE, et al: A single
nucleotide polymorphism in the MDM2 promoter attenuates the p53
tumor suppressor pathway and accelerates tumor formation in humans.
Cell. 119:591–602. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Dumont P, Leu JI, Della Pietra AC III,
George DL and Murphy M: The codon 72 polymorphic variants of p53
have markedly different apoptotic potential. Nat Genet. 33:357–365.
2003. View
Article : Google Scholar : PubMed/NCBI
|
|
24
|
Khan SA, Davidson BR, Goldin R, et al:
Guidelines for the diagnosis and treatment of cholangiocarcinoma:
consensus document. Gut. 51(Suppl 6): 1–9. 2002.PubMed/NCBI
|
|
25
|
Hartman M, Loy EY, Ku CS and Chia KS:
Molecular epidemiology and its current clinical use in cancer
management. Lancet Oncol. 11:383–390. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hattersley AT and McCarthy MI: What makes
a good genetic association study? Lancet. 366:1315–1323. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Bond GL, Hirshfield KM, Kirchhoff T, et
al: MDM2 SNP309 accelerates tumor formation in a gender-specific
and hormone-dependent manner. Cancer Res. 66:5104–5110. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Bond GL and Levine AJ: A single nucleotide
polymorphism in the p53 pathway interacts with gender,
environmental stresses and tumor genetics to influence cancer in
humans. Oncogene. 26:1317–1323. 2007. View Article : Google Scholar
|
|
29
|
Zimmer V, Widmann T, Muller M, et al:
Genotypic interaction and gender specificity of common genetic
variants in the p53/mdm2 network in Crohn’s disease. Digestion.
81:246–251. 2010.PubMed/NCBI
|
|
30
|
Jones JS, Chi X, Gu X, Lynch PM, Amos CI
and Frazier ML: p53 polymorphism and age of onset of hereditary
nonpolyposis colorectal cancer in a Caucasian population. Clin
Cancer Res. 10:5845–5849. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Shen H, Zheng Y, Sturgis EM, Spitz MR and
Wei Q: P53 codon 72 polymorphism and risk of squamous cell
carcinoma of the head and neck: a case-control study. Cancer Lett.
183:123–130. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Welzel TM, Graubard BI, El-Serag HB, et
al: Risk factors for intrahepatic and extrahepatic
cholangiocarcinoma in the United States: a population-based
case-control study. Clin Gastroenterol Hepatol. 5:1221–1228. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Thomas M, Kalita A, Labrecque S, Pim D,
Banks L and Matlashewski G: Two polymorphic variants of wild-type
p53 differ biochemically and biologically. Mol Cell Biol.
19:1092–1100. 1999.PubMed/NCBI
|
|
34
|
Pim D and Banks L: p53 polymorphic
variants at codon 72 exert different effects on cell cycle
progression. Int J Cancer. 108:196–199. 2004. View Article : Google Scholar : PubMed/NCBI
|
